Statement of American Muslim Health Professionals (AMHP)
This week, Congress passed the Consolidated Appropriations Act for 2023, which includes significant legislation to address the worsening overdose crisis. American Muslim Health Professionals (AMHP) applauds the passage of the bill and its Mainstreaming Addiction Treatment (MAT) Act provision, which will remove federal barriers to medications for opioid use disorder, reduce stigma, and increase access to life-saving treatment that prevents overdoses and supports recovery.
We thank Reps. Paul Tonko, Mike Turner, Anthony Gonzalez, and Sens. Maggie Hassan and Lisa Murkowksi for their sponsorship of the MAT Act and their tireless work to ensure that the bill was included in the omnibus. We also thank Speaker Nancy Pelosi, Majority Leader Chuck Schumer, Leader Mitch McConnell, the House Energy and Commerce Committee Chair Frank Pallone Jr. and Ranking Member Cathy McMorris Rodgers, the Senate HELP Committee Chair Patty Murray and Ranking Member Richard Burr, and Rep. David Trone for their leadership in passing the MAT Act.
In 2021, the United States lost nearly 108,000 people to drug overdoses — an unfathomable tragedy. Each person who died from an overdose has left behind family members, friends, and communities. Without action, we are projected to lose one million more loved ones to drug overdoses by 2030.
The MAT Act will help turn the tide of the overdose crisis by saving thousands of lives from overdoses and supporting long-term recovery from opioid use disorder. Overdose deaths are preventable through evidence-based treatment, including medication that prevents painful withdrawal symptoms and that stems opioid cravings. But due to outdated federal rules, only about 1 in 10 people in need receive medications for opioid use disorder, including buprenorphine, which is recognized as a gold standard of care.
These outdated federal rules include mandatory registration with SAMHSA and the DEA to prescribe buprenorphine, limits on the number of patients with opioid use disorder that health care providers can treat with buprenorphine, and other onerous requirements that stigmatize one of the most effective treatments for opioid use disorder, patients with the condition, and the health care providers who treat them. Due to these onerous federal rules, fully 40% of U.S. counties lack a single health care provider who can prescribe buprenorphine for opioid use disorder.
The MAT Act removes these onerous, outdated federal rules and empowers all health care providers with a standard controlled medication license to prescribe buprenorphine for opioid use disorder, just as they prescribe other essential medications. The MAT Act will help destigmatize a gold standard of care for opioid use disorder and will integrate substance use disorder treatment into primary care and behavioral health care practices, emergency departments, hospitals, and the health care system as a whole. By passing the MAT Act, Congress has acted to prevent future overdose deaths and support people with substance use disorder in securing recovery.
AMHP is one of nearly 550 organizations that called on Congress and the White House to pass the MAT Act. This Congress, the MAT Act won more than 275 Democratic, Republican, and Independent cosponsors in the House (H.R.1384) and the Senate (S.445) – a testament to the policy’s overwhelming bipartisan support. Both President Biden’s and President Trump’s former Directors of the Office of National Drug Control Policy called for Congress to pass the MAT Act. They joined the bipartisan U.S. Commission on Combating Synthetic Opioid Trafficking in urging Congress to adopt the policy. The MAT Act was among the most broadly supported pieces of overdose prevention legislation introduced this session.
Congress’ passage of the MAT Act is a significant step towards ensuring that everyone with substance use disorder receives the care they need to be well. AMHP looks forward to President Biden’s signing of this bill that will open the doors of recovery to countless people in need.